Vivoryon Therapeutics N.V.
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
05 okt 2016 - 17:46
Statutaire naam
Vivoryon Therapeutics N.V.
Titel
Probiodrug launches capital increase by means of an accelerated bookbuild offering
Bericht
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA
Probiodrug launches capital increase by means of an accelerated bookbuild offering
HALLE/SAALE, Germany, 5 October 2016 - Probiodrug AG (the "Company") (Euronext Amsterdam: PBD), a biopharmaceutical company developing novel therapeutic solutions to treat Alzheimer's disease (AD), intends to issue up to 744,248 new shares (the "New Shares"). The New Shares represent up to approximately 10% of the Company's issued share capital. In this context, the Company's management board has resolved, with approval of the Company's supervisory board, to increase the share capital of the Company by EUR 744,248, from EUR 7,442,487 to EUR 8,186,735, against cash contribution by utilizing partially the Company's authorized capital. The pre-emptive rights of the Company's existing shareholders are excluded. The offering will take place by means of an accelerated bookbuilding.
Gerelateerde downloads
Datum laatste update: 01 september 2024